The Novacyt share price is flying: here’s what I’d do next

Covid 19 testing is ramping up. Harshil Patel discusses a diagnostics leader and what the Novacyt share price might do next.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Novacyt (LSE: NCYT) shares have rocketed this year. At the start of 2020, the Novacyt share price was roughly 15p. After a phenomenal run this year, the shares are currently trading at over 1,100p.

Why is this? Well, Novacyt is a France-based diagnostics company that’s at the forefront of Covid-19 diagnostics and testing.

It’s very quickly on its way to becoming a world leader in the field, distributing its products to over 130 countries around the world. It’s also one of the leading suppliers of Covid-19 tests to the Department of Health & Social Care in the UK.

The Novacyt share price was relatively lacklustre until Covid-19 dramatically increased demand for diagnostics and testing for the global virus this year. The World Health Organisation has consistently repeated its message to “test, test, test”. The prospects for this biotechnology mid-cap have significantly improved, in my opinion.

Rapidly rising growth

Revenue has been growing over the years, but nothing compared with this year. In the first half of 2020, revenue rose a whopping 900% to €72.4m and profit margin increased to 83% from 63%. The company was loss-making until this year. But pre-tax profit swung from a loss of €1.2m to a gain of €46.1m.

Growth is set to continue well into 2021. Novacyt has good visibility of orders and several new Covid-19 related products in the pipeline. Full-year revenues are expected to exceed €150m. Investors have started to take notice as the Novacyt share price surge shows. 

Has the Novacyt share price flown too far?

But is the share price rise overdone? Perhaps in the short term, given its rapid ascent in recent weeks. However, I’d say that the upside for this company is only just getting noticed. I’d still consider these shares as part of a balanced portfolio in a Stocks and Shares ISA. Very few brokers currently follow this stock and I wouldn’t be surprised if it gets more attention as the amount of institutional research grows.

There’s still much more to get excited about. I reckon there’s a good chance of seeing new contract wins, both in the UK and globally. The UK government scheme Operation Moonshot has begun with a trial of rapid mass testing for Covid-19 in hospitals. The plan is to also roll it out to other organisations like schools and universities.

After a tripling of the Novacyt share price in just a couple of months, the shares aren’t without risk though. If a vaccine is developed and deployed, the demand for rapid testing may potentially decline. Another risk is that a competitor develops a faster Covid-19 test.

But my view is that rapid testing is here to stay for the near future, and an effective vaccine could be some way away. Winter is coming, and Novacyt looks well-positioned to significantly benefit from increased global demand for Covid-19 testing.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Harshil Patel owns shares in Novacyt. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »

Investing Articles

Are HSBC shares a FTSE bargain? Here’s what the charts say!

There are plenty of dirt-cheap FTSE 100 banking stocks for investors to choose from today. Our writer Royston Wild believes…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

Just released: Share Advisor’s latest ‘Hold’ recommendation [PREMIUM PICKS]

In our Share Advisor newsletter service, we provide buy, sell, and hold guidance for our universe of recommendations.

Read more »

Investing Articles

Investing £5 a day could help me build a second income of £329 a month!

This Fool explains how £5 a day, or one less takeaway coffee, could help her build a monthly second income…

Read more »

Smart young brown businesswoman working from home on a laptop
Investing Articles

2 FTSE income stocks investors should consider buying in April

Income stocks are a great way to build wealth. Our writer details two picks she believes investors should consider snapping…

Read more »

Investing Articles

What might the 5-year price chart tell us about BT shares?

Christopher Ruane considers what clues the long-term performance of BT shares might offer him about business performance and whether to…

Read more »